Skip to main content
SpringerLink
Log in

Comparative Pharmacology of S(+)-Ibuprofen and (RS)-Ibuprofen

  • Clinical Rheumatology
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Racemic ibuprofen, which contains equal quantities of R(-)-ibuprofen and S(+)-ibuprofen, has been used as an anti-inflammatory and analgesic agent for over 30 years. Although the S(+)-enantiomer is capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations, R(-)-ibuprofen is not a COX inhibitor. The two enantiomers of ibuprofen are therefore different in terms of their pharmacological properties and may be regarded as two different ‘drugs’. They also differ in terms of their metabolic profiles. For example, R(-)-ibuprofen becomes involved in pathways of lipid metabolism and is incorporated into triglycerides along with endogenous fatty acids. S(+)-Ibuprofen does not appear to become involved in these unusual metabolic reactions, which is why S(+)-ibuprofen is regarded as being metabolically ‘cleaner’ than racemic ibuprofen. When racemic ibuprofen is given to humans, a substantial fraction of the dose of R(-)-ibuprofen (50%-60%) undergoes ‘metabolic inversion’ to yield S(+)-ibuprofen. On this basis, it has been argued that to obtain clinical effects that are comparable to those of a given dose of racemic ibuprofen, the dose of S(+)-ibuprofen would need to be about 75% of the dose of the racemate. However, this ‘pharmacokinetic’ rationale does not take into account the fact that inversion is not instantaneous, that there is variability in the extent of inversion between individuals, and that the kinetics of inversion may differ depending on the dosing situations. For example, the extent of inversion appears to be reduced when the racemate is given to patients experiencing acute pain. Recent studies have demonstrated that the clinical benefits of racemic ibuprofen can be derived from the administration of the single S(+)-enantiomer at a dose that is half that of the racemate. For example, 200 mg of S(+)-ibuprofen has been found to be superior or at least equivalent to 400 mg of the racemate in the relief of dental pain. Possible explanations for this higher than expected efficacy of S(+)-ibuprofen are considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Millership JS, Fitzpatrick A. Commonly used chiral drugs: a survey. Chirality 1993;5:573–6.

    Article  CAS  PubMed  Google Scholar 

  2. Ariens EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984;26:663–8.

    Article  CAS  PubMed  Google Scholar 

  3. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998;34:101–54.

    Article  CAS  PubMed  Google Scholar 

  4. Evans AM. Pharmacodynamics and pharmacokinetics of the pro fens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen. J Clin Pharmacol 1996;36:S7–15.

    Google Scholar 

  5. Rainsford KD. Pharmacology and toxicology of ibuprofen. In: Rainsford KD, ed. Ibuprofen. A critical bibliographic review. London. Taylor & Francis, 2000.

    Google Scholar 

  6. Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992;42:237–56.

    Article  CAS  PubMed  Google Scholar 

  7. McCormack K, Brune K. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal antiinflammatory drugs. Drugs 1991;41:533–47.

    Article  CAS  PubMed  Google Scholar 

  8. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232–5.

    CAS  Google Scholar 

  9. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693–704.

    Article  CAS  PubMed  Google Scholar 

  10. Wechter WW. Drug chirality: on the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemate. J Clin Pharmacol 1992;34:1036–42.

    Article  Google Scholar 

  11. Adams SS, Bresloff P, Mason CG. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (-)-isomer. J Pharm Pharmacol 1976;28:256–7.

    Article  CAS  PubMed  Google Scholar 

  12. Baillie TA, Adams WJ, Kaiser DG et al. Mechanistic studies of the metabolic chiral inversion of R(-)-ibuprofen in humans. J Pharmacol Exp Ther 1989;249:517–23.

    CAS  PubMed  Google Scholar 

  13. Rudy AC, Bradley JD, Ryan SI, Kalasinski LA, Xiaotao Q, Hall SD. Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. Ther Drug Monit 1992;14:464–70.

    Article  CAS  PubMed  Google Scholar 

  14. Rudy AC, Knight PM, Brater DC, Hall SD. Stereoselective metabolism of ibuprofen in humans: administration of R-, S- and racemic ibuprofen. J Pharmacol Exp Ther 1991;259:1133–9.

    CAS  PubMed  Google Scholar 

  15. Lee EJD, Williams K, Day R, Graham G, Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985;19:669–74.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Aiba T, Tse MM, Lin ET, Koizumu T. Effect of dosage form on stereoisomeric inversion of ibuprofen in volunteers. Biol Pharm Bull 1999; 22:616–22.

    Article  CAS  PubMed  Google Scholar 

  17. Mehvar R, Jamali F. Pharmacokinetic analysis of the enantiomeric inversion of chiral nonsteroidal antiinflammatory drugs. Pharm Res 1988;5:76–9.

    Article  CAS  PubMed  Google Scholar 

  18. Jamali F, Kunz-Dober CM. Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. Br J Clin Pharmacol 1999;47:391–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Scheuerer S, Hall SD, Williams KM, Geisslinger G. Effect of clofibrate on the chiral inversion of ibuprofen in healthy volunteers. Clin Pharmacol Ther 1998;64:168–76.

    Article  CAS  PubMed  Google Scholar 

  20. Williams K, Day R, Knihinicki R, Duffield A. The stereoselective uptake of ibuprofen enantiomers into adipose tissue. Biochem Pharmacol 1986;35:3403–5.

    Article  CAS  PubMed  Google Scholar 

  21. Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984;15:1213–19.

    Article  CAS  PubMed  Google Scholar 

  22. Hayball PJ. Formation and reactivity of acyl glucuronides. The influence of chirality: Chirality 1995;7:1–9.

    Article  CAS  PubMed  Google Scholar 

  23. Sallustio BC, Sabordo L, Evans AM, Nation RL. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr Drug Metab 2000; 1:163–80.

    Article  CAS  PubMed  Google Scholar 

  24. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as detoxification mechanism? Drug Metab Rev 1992; 24:5–48.

    Article  CAS  PubMed  Google Scholar 

  25. Castillo M, Lam YWF, Dooley MA, Stahl E, Smith PC. Disposition and covalent binding of ibuprofen and its acyl glucuronide in the elderly. Clin Pharmacol Ther 1995;57:636–44.

    Article  CAS  PubMed  Google Scholar 

  26. Dionne RA, McCullagh L. Enhanced analgesia and suppression of plasma beta-endorphin by the S(+)-isomer of ibuprofen. Clin Pharmacol Ther 1998;63:694–701.

    Article  CAS  PubMed  Google Scholar 

  27. Singer F, Mayrhofer F, Klein G, Hawel R, Kollenz CJ. Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAX osteoarthritis index. Int J Clin Pharmacol Ther 2000;38:15–24.

    Article  CAS  PubMed  Google Scholar 

  28. Rahlfs J. Reevaluation of some double-blind, randomized studies of dexibuprofen (Seractil): A state-of-the-art overview. Clin Pharmacol 1996;36:S33–40.

    Google Scholar 

  29. Phleps W. ‘Overview on Clincial Data of Dexibuprofen’. In: 2001 Symposium on S(+)Ibuprofen Dexibuprofen in Modern Pain Treatment. 1991;20(Suppl l):20–6.

    Google Scholar 

  30. Neupert W, Brugger R, Euchenhofer C, Brune K, Geisslinger G. Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases. Br J Pharmacol 1997;22:487–92.

    Article  Google Scholar 

  31. Boneborg EM, Zou M-H, Ullrich V. Inhibition of cyclooxygenase-1 and -2 by R(-)- and S(+)-ibuprofen. J Clin Pharmacol 1996;36:S16–19.

    Google Scholar 

  32. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenase. Biochem J 1999;339:607–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy and Medical Sciences, University of South Australia, North Terrace, Adelaide, 5000, South Australia

    A. M. Evans (Associate Professor)

Authors
  1. A. M. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. Evans.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Evans, A.M. Comparative Pharmacology of S(+)-Ibuprofen and (RS)-Ibuprofen. Clin Rheumatol 20 (Suppl 1), 9–14 (2001). https://doi.org/10.1007/BF03342662

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03342662

Keywords

Search

Navigation